Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Common Equity (2016 - 2025)

Aethlon Medical filings provide 15 years of Common Equity readings, the most recent being $5.1 million for Q1 2025.

  • On a quarterly basis, Common Equity fell 11.15% to $5.1 million in Q1 2025 year-over-year; TTM through Mar 2025 was $5.1 million, a 11.15% decrease, with the full-year FY2025 number at $5.1 million, down 11.15% from a year prior.
  • Common Equity hit $5.1 million in Q1 2025 for Aethlon Medical, up from $4.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $24.7 million in Q2 2021 to a low of $4.3 million in Q4 2024.
  • Median Common Equity over the past 5 years was $13.1 million (2023), compared with a mean of $13.1 million.
  • Biggest five-year swings in Common Equity: surged 82.83% in 2022 and later tumbled 61.72% in 2024.
  • Aethlon Medical's Common Equity stood at $20.6 million in 2021, then decreased by 15.95% to $17.3 million in 2022, then plummeted by 55.95% to $7.6 million in 2023, then plummeted by 43.06% to $4.3 million in 2024, then grew by 18.21% to $5.1 million in 2025.
  • The last three reported values for Common Equity were $5.1 million (Q1 2025), $4.3 million (Q4 2024), and $6.0 million (Q3 2024) per Business Quant data.